Patent application number | Description | Published |
20080269846 | DEVICE FOR TREATMENT OF BLOOD VESSELS USING LIGHT - Light generating devices for illuminating portions of vascular tissue to administer photodynamic therapy, and usable with, or including a distal protection device. A first device includes a hollow tip, a flushing lumen, a guidewire lumen, and at least one of a light source, and a hollow light transmissive shaft that is adapted to accommodate a light source. If desired, the device can include a balloon, so that a portion of a body lumen between the balloon and the distal protection device is isolated when the balloon is inflated. A second device includes inner and outer catheters, the outer catheter including a balloon, and the inner catheter including a light source encompassed by another balloon. Yet another device is a catheter having two balloons and a sleeve extending there between. Within the sleeve, the catheter includes a light source and an expanding member. | 10-30-2008 |
20090216300 | METHOD AND APPARATUS FOR LIGHT-ACTIVATED DRUG THERAPY - A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer. | 08-27-2009 |
20100035321 | SYSTEMS, DEVICES, AND, METHODS FOR RELEASING BIOMASS CELL COMPONENTS - Systems, devices, and methods for releasing one or more cell components from a photosynthetic organism. A bioreactor system is operable for growing photosynthetic organisms. Some of the methods include contacting the photosynthetic organism with an energy-activatable sensitizer, and activating the energy-activatable sensitizer, thereby releasing a cellular component from at least one of, for example, a membrane structure, tubule, vesicle, cisterna, organelle, cell compartment, plastid, or mitochondrion, associated with the photosynthetic organisms. | 02-11-2010 |
20100036311 | ENHANCEMENT OF LIGHT ACTIVATED THERAPY BY IMMUNE AUGMENTATION USING ANTI-CTLA-4 ANTIBODY - The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above a normal level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the region treated using light). By further stimulating the immune system using an anti-CTLA-4 antibody, the systemic destruction of abnormal tissue is enhanced. | 02-11-2010 |
20100121252 | NON-INVASIVE VASCULAR TREATMENT SYSTEMS, DEVICES, AND METHODS OF USING THE SAME - An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask. | 05-13-2010 |
20100145415 | LIGHT DELIVERY SYSTEM - A light delivery system to provide light treatment to a patient includes a catheter assembly having a plurality of light sources that transmit light towards a target site within a patient. In one embodiment, the light delivery system has a plurality of light sources mounted to a flexible transparent base that extends at least partially through a distal tip of the catheter assembly. The light sources can be wire bonded or mounted in a flip chip arrangement onto the base. In one embodiment to produce the distal tip, an array of light energy sources can be held by an array of holders of a fixture device. A vacuum is applied to secure each light energy source in a corresponding holder. While the vacuum is applied, the energy sources are electrically connected by wire bonding. The vacuum can be reduced or stopped thereby permitting removal of the light energy sources from the fixture device. | 06-10-2010 |
20100274330 | DEVICE FOR TREATMENT OF BLOOD VESSELS USING LIGHT - Light generating devices for illuminating portions of vascular tissue to administer photodynamic therapy, and usable with, or including a distal protection device. A first device includes a hollow tip, a flushing lumen, a guidewire lumen, and at least one of a light source, and a hollow light transmissive shaft that is adapted to accommodate a light source. If desired, the device can include a balloon, so that a portion of a body lumen between the balloon and the distal protection device is isolated when the balloon is inflated. A second device includes inner and outer catheters, the outer catheter including a balloon, and the inner catheter including a light source encompassed by another balloon. Yet another device is a catheter having two balloons and a sleeve extending there between. Within the sleeve, the catheter includes a light source and an expanding member. | 10-28-2010 |
20100305436 | SYSTEMS, DEVICES, AND METHODS FOR PHOTOACTIVE ASSISTED RESECTION - A method and system is used to locate tissue for removal during a resection. The system includes a container that holds a photoactivatable agent capable of binding with unwanted tissue at a treatment site, a light source, and a viewing device. The light source is adapted to continuously output light that causes fluorescence of the photoactivatable agent in unwanted tissue. The system provides fluorescence-enhanced viewing of the treatment site through the viewing device. The viewing device has a filter that filters out light from the light source that is reflected from the treatment site while allowing a fluorescence emission from the photoactivatable agent to pass therethrough to each eye of the user. The light from the light source and the fluorescence emission are in different regions of the energy spectrum. | 12-02-2010 |
20110008372 | ENHANCEMENT OF LIGHT ACTIVATED DRUG THERAPY THROUGH COMBINATION WITH OTHER THERAPEUTIC AGENTS - The efficacy of light activated therapy treatment is enhanced by use of additional therapeutic agents. Abnormal tissue is destroyed by light activated therapy, and the associated administration of one or more additional therapeutic agents can synergistically enhance the therapy. For example, the concepts disclosed herein encompass the use of the following agents in combination with light activated drug therapy: (1) agents that selectively inhibit heat shock protein 90 (Hsp90); (2) agents that inhibit the Hedgehog pathway (which is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, and which is implicated in many of the most deadly cancers); and, (3) agents for reducing the anti-apoptotic effects of Bcl-2 or Bcl-xL. These agents can be used with light activated drug therapy individually, or in various combinations and permutations. | 01-13-2011 |
20110009464 | IMMUNE SYSTEM STIMULATION BY LIGHT THERAPY INDUCED APOPTOTIC CELL DEATH IN ABNORMAL TISSUE - The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above the pre-therapy level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the area treated using light), so long as the light therapy conditions favor apoptosis over necrosis. The volume of abnormal tissue destroyed is maximized to the extent possible, reducing tumor load, which reduces an amount of immunosuppressive factors in the body, enabling stimulation of the immune system to be successful. | 01-13-2011 |
20110077464 | MEDICAL APPARATUS EMPLOYING FLEXIBLE LIGHT STRUCTURES AND METHODS FOR MANUFACTURING SAME - A method of manufacture and medical apparatus that provides an apparatus useful in illuminating at least a portion of a lumen of a body. The apparatus includes an elongated flexible member and a polymer encasement portion encasing a plurality of light emitters. The light emitters may be electrically coupled to one another without the use of wire bonds, and in some embodiments may be coupled without intervening electrical paths or traces. A maximum cross-sectional dimension of the polymer encasement portion may be less than twice a dimension of one of the light emitters. In some embodiments the maximum cross-sectional dimension is less than or equal to the sum of the dimension of one of the light emitters and a marginal dimension by which an outer portion of the polymer encasement portion extends beyond the light emitter. Light emitters may be arranged linearly, helically or in partially overlapping back-to-back relation. | 03-31-2011 |
20110236402 | ENHANCEMENT OF LIGHT ACTIVATED THERAPY BY IMMUNE AUGMENTATION USING ANTI-CTLA-4 ANTIBODY - The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above a normal level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the region treated using light). By further stimulating the immune system using an anti-CTLA-4 antibody, the systemic destruction of abnormal tissue is enhanced. | 09-29-2011 |
20120089207 | LIGHT TRANSMISSION SYSTEM FOR PHOTOREACTIVE THERAPY - A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate. | 04-12-2012 |
20120149986 | MEDICAL APPARATUS EMPLOYING FLEXIBLE LIGHT STRUCTURES - A method of manufacture and medical apparatus that provides an apparatus useful in illuminating at least a portion of a lumen of a body. The apparatus includes an elongated flexible member and a polymer encasement portion encasing a plurality of light emitters. The light emitters may be electrically coupled to one another without the use of wire bonds, and in some embodiments may be coupled without intervening electrical paths or traces. A maximum cross-sectional dimension of the polymer encasement portion may be less than twice a dimension of one of the light emitters. In some embodiments the maximum cross-sectional dimension is less than or equal to the sum of the dimension of one of the light emitters and a marginal dimension by which an outer portion of the polymer encasement portion extends beyond the light emitter. Light emitters may be arranged linearly, helically or in partially overlapping back-to-back relation. | 06-14-2012 |